Baidu
map

患者招募:以软组织肉瘤为主的晚期恶性实体瘤的TAEST16001临床试验

2020-04-14 MedSci MedSci原创

广东香雪精准医疗技术有限公司是广州市香雪制药股份有限公司子公司,前身是2012年成立的香雪生命科学研究中心,主要致力于研发具有我国自主知识产权的针对肿瘤的特异性T细胞过继免疫治疗的新方法,简称为TCR

广东香雪精准医疗技术有限公司是广州市香雪制药股份有限公司子公司,前身是2012年成立的香雪生命科学研究中心,主要致力于研发具有我国自主知识产权的针对肿瘤的特异性T细胞过继免疫治疗的新方法,简称为TCR-T免疫治疗技术。

另外,除了开发新一代基因抗肿瘤新药和T细胞基因治疗临床应用技术,香雪精准也是全球第二家开展高亲和性T细胞受体平台技术基因治疗技术的研发机构。此次公布的临床试验项目是针对于实体瘤治疗的国内首个TCR-T项目,对于国内免疫治疗领域是一次里程碑式的事件。

“TAEST16001治疗肿瘤抗原NY-ESO-1表达阳性(基因型为HLA-A*02:01)的以软组织肉瘤为主的晚期恶性实体瘤患者的开放、单臂、早期临床研究”现已开始招募受试者。

基本入选条件:

  1. 年龄18~70岁,包含18岁和70岁

  2. 病理学诊断明确的晚期恶性实体瘤,包括软组织肉瘤、原发性肝脏恶性肿瘤、卵巢恶性肿瘤、非小细胞肺癌(NSCLC)和乳腺癌等

  3. 经标准治疗失败或缺乏有效治疗

  4. 至少有1个可测量病灶

  5. 基因型为HLA-A*02:01且肿瘤抗原NY-ESO-1表达阳性

  6. 育龄女性或男性同意在研究期间及细胞治疗后1年内采取有效的避孕措施

  7. 育龄期女性血妊娠检查结果应为阴性

 

符合以上入选标准且有意向的患者请联系

邱助理 

18127997904

研究中心:中山大学肿瘤防治中心

张星主任(门诊周三、四、五上午--8:30-12:00)

翁德胜教授(门诊周二下午--14:30-17:30)

地址:广东省广州市越秀区东风东路651号

 

(以上招募信息已经过伦理委员会批准使用)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051545, encodeId=43ce205154530, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 05 03:41:01 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738415, encodeId=9eed1e3841562, content=<a href='/topic/show?id=c3e01e0804d' target=_blank style='color:#2F92EE;'>#TAEST16001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17080, encryptionId=c3e01e0804d, topicName=TAEST16001)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aff34436240, createdName=陆成振, createdTime=Fri May 22 03:41:01 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381888, encodeId=69a438188894, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 19 08:13:11 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381801, encodeId=e6e9381801a4, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Apr 17 08:07:26 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420456, encodeId=369514204561e, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548549, encodeId=05b515485496d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381721, encodeId=2bb9381e21c5, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Apr 15 08:31:57 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051545, encodeId=43ce205154530, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 05 03:41:01 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738415, encodeId=9eed1e3841562, content=<a href='/topic/show?id=c3e01e0804d' target=_blank style='color:#2F92EE;'>#TAEST16001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17080, encryptionId=c3e01e0804d, topicName=TAEST16001)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aff34436240, createdName=陆成振, createdTime=Fri May 22 03:41:01 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381888, encodeId=69a438188894, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 19 08:13:11 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381801, encodeId=e6e9381801a4, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Apr 17 08:07:26 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420456, encodeId=369514204561e, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548549, encodeId=05b515485496d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381721, encodeId=2bb9381e21c5, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Apr 15 08:31:57 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051545, encodeId=43ce205154530, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 05 03:41:01 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738415, encodeId=9eed1e3841562, content=<a href='/topic/show?id=c3e01e0804d' target=_blank style='color:#2F92EE;'>#TAEST16001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17080, encryptionId=c3e01e0804d, topicName=TAEST16001)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aff34436240, createdName=陆成振, createdTime=Fri May 22 03:41:01 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381888, encodeId=69a438188894, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 19 08:13:11 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381801, encodeId=e6e9381801a4, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Apr 17 08:07:26 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420456, encodeId=369514204561e, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548549, encodeId=05b515485496d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381721, encodeId=2bb9381e21c5, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Apr 15 08:31:57 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
    2020-04-19 飛歌

    学习了很有用不錯

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2051545, encodeId=43ce205154530, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 05 03:41:01 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738415, encodeId=9eed1e3841562, content=<a href='/topic/show?id=c3e01e0804d' target=_blank style='color:#2F92EE;'>#TAEST16001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17080, encryptionId=c3e01e0804d, topicName=TAEST16001)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aff34436240, createdName=陆成振, createdTime=Fri May 22 03:41:01 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381888, encodeId=69a438188894, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 19 08:13:11 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381801, encodeId=e6e9381801a4, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Apr 17 08:07:26 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420456, encodeId=369514204561e, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548549, encodeId=05b515485496d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381721, encodeId=2bb9381e21c5, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Apr 15 08:31:57 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
    2020-04-17 一天没事干

    很好的学习机会

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2051545, encodeId=43ce205154530, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 05 03:41:01 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738415, encodeId=9eed1e3841562, content=<a href='/topic/show?id=c3e01e0804d' target=_blank style='color:#2F92EE;'>#TAEST16001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17080, encryptionId=c3e01e0804d, topicName=TAEST16001)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aff34436240, createdName=陆成振, createdTime=Fri May 22 03:41:01 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381888, encodeId=69a438188894, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 19 08:13:11 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381801, encodeId=e6e9381801a4, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Apr 17 08:07:26 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420456, encodeId=369514204561e, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548549, encodeId=05b515485496d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381721, encodeId=2bb9381e21c5, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Apr 15 08:31:57 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
    2020-04-16 qilu_qi
  6. [GetPortalCommentsPageByObjectIdResponse(id=2051545, encodeId=43ce205154530, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 05 03:41:01 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738415, encodeId=9eed1e3841562, content=<a href='/topic/show?id=c3e01e0804d' target=_blank style='color:#2F92EE;'>#TAEST16001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17080, encryptionId=c3e01e0804d, topicName=TAEST16001)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aff34436240, createdName=陆成振, createdTime=Fri May 22 03:41:01 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381888, encodeId=69a438188894, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 19 08:13:11 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381801, encodeId=e6e9381801a4, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Apr 17 08:07:26 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420456, encodeId=369514204561e, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548549, encodeId=05b515485496d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381721, encodeId=2bb9381e21c5, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Apr 15 08:31:57 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2051545, encodeId=43ce205154530, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Aug 05 03:41:01 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738415, encodeId=9eed1e3841562, content=<a href='/topic/show?id=c3e01e0804d' target=_blank style='color:#2F92EE;'>#TAEST16001#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17080, encryptionId=c3e01e0804d, topicName=TAEST16001)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5aff34436240, createdName=陆成振, createdTime=Fri May 22 03:41:01 CST 2020, time=2020-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381888, encodeId=69a438188894, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Apr 19 08:13:11 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381801, encodeId=e6e9381801a4, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Apr 17 08:07:26 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420456, encodeId=369514204561e, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548549, encodeId=05b515485496d, content=<a href='/topic/show?id=6a4756229d9' target=_blank style='color:#2F92EE;'>#招募#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56229, encryptionId=6a4756229d9, topicName=招募)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=038c14086626, createdName=ms1260584454294838, createdTime=Thu Apr 16 13:41:01 CST 2020, time=2020-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381721, encodeId=2bb9381e21c5, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Apr 15 08:31:57 CST 2020, time=2020-04-15, status=1, ipAttribution=)]
    2020-04-15 一天没事干

    很好的学习机会

    0

相关资讯

Radiology:软组织肉瘤MRI征象与组织学分级及患者预后的相关性

背景:软组织肉瘤(STS)的诊断治疗依赖于组织学分级,对于预后及活检常规评价非常有意义。然而,由于肿瘤异质性,组织学分级也会出现错误性低估。本研究旨在识别与高级别STS(3级)相关的MRI征象以及MRI征象与患者生存期的相关性。

JAMA:阿霉素联合olaratumab治疗晚期软组织肉瘤

阿霉素联合olaratumab对晚期软组织肉瘤生存期无显著影响

Brit J Cancer:父亲职业暴露与儿童骨骼肿瘤和软组织肉瘤的关系

尽管这项研究规模大且不受偏倚影响,但应谨慎解释该研究的结果。研究人员进行了许多显著性检验,并且机会性结果也是可预期。然而,研究人员发现ESFT与父亲接触纺织品粉尘之间的关联可能支持文献中的相关建议。

NCCN临床实践指南:软组织肉瘤(2019.V4)

2019年9月,美国国家综合癌症网络(NCCN)发布了软组织肉瘤指南2019年第4版,指南主要内容包括: 指南更新摘要 软组织肉瘤 ·肢体/躯干体表,头颈 ·腹膜后/腹腔内 胃肠道间质瘤的活组织检查原则 胃肠道间质瘤的病理评估原则 胃肠道间质瘤手术治疗原则 ·硬纤维瘤(侵袭性纤维瘤病) ·横纹肌肉瘤 肉瘤标本病理评估的原则 肉瘤辅助诊断技术应用原则 手术治疗原则 放疗指南 软组织肉瘤的系统治疗 分

欧盟委员会授予分泌酶抑制剂Nirogacestat治疗软组织肉瘤的孤儿药物称号

SpringWorks的口服选择性小分子γ-分泌酶抑制剂nirogacestat已被欧盟指定为治疗软组织肉瘤的孤儿药物。该公司目前正在为III期DeFi试验招募患者,以评估nirogacestat治疗硬纤维瘤成人患者,硬纤维瘤是肉瘤中的一种软组织肿瘤。

新辅助治疗在软组织肉瘤中的应用及靶向治疗的思考

软组织肉瘤类型众多,异质性强,对化疗的敏感性不一,治疗策略不一而足,亦无统一共识。靶向治疗作为新兴治疗在软组织肉瘤中应用的认知远不如化疗。针对新辅助治疗、以抗血管生成药物为代表的靶向治疗在软组织肉瘤中的应用等相关问题,东部战区总医院吴苏稼教授和解放军九六〇医院于秀淳教授,详情如下。

Baidu
map
Baidu
map
Baidu
map